The availability of SCUBE3 as a treatment is not imminent. It is still in the preclinical and early development phases, with clinical trials expected to take several years. Estimates from sources indicate it could take 5 to 10 years before SCUBE3 is available on the market, largely because drug approval processes typically take around 5 years and SCUBE3 has yet to clear all clinical trial stages. A startup named Amplifica is currently developing SCUBE3, but its progress is uncertain and dependent on funding and successful trials. Therefore, SCUBE3 will likely not be available for several more years, potentially around 2030 or beyond.
